Literature DB >> 33466790

Targeting the Ubiquitin Signaling Cascade in Tumor Microenvironment for Cancer Therapy.

Qi Liu1, Bayonle Aminu1, Olivia Roscow1, Wei Zhang1,2.   

Abstract

Tumor microenvironments are composed of a myriad of elements, both cellular (immune cells, cancer-associated fibroblasts, mesenchymal stem cells, etc.) and non-cellular (extracellular matrix, cytokines, growth factors, etc.), which collectively provide a permissive environment enabling tumor progression. In this review, we focused on the regulation of tumor microenvironment through ubiquitination. Ubiquitination is a reversible protein post-translational modification that regulates various key biological processes, whereby ubiquitin is attached to substrates through a catalytic cascade coordinated by multiple enzymes, including E1 ubiquitin-activating enzymes, E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases. In contrast, ubiquitin can be removed by deubiquitinases in the process of deubiquitination. Here, we discuss the roles of E3 ligases and deubiquitinases as modulators of both cellular and non-cellular components in tumor microenvironment, providing potential therapeutic targets for cancer therapy. Finally, we introduced several emerging technologies that can be utilized to develop effective therapeutic agents for targeting tumor microenvironment.

Entities:  

Keywords:  E3 ligase; cancer-associated fibroblasts; deubiquitinase; extracellular matrix; hypoxia; immune cells; inhibitors; tumor microenvironment; ubiquitin variants; ubiquitination

Mesh:

Substances:

Year:  2021        PMID: 33466790      PMCID: PMC7830467          DOI: 10.3390/ijms22020791

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  133 in total

1.  Conformational dynamics control ubiquitin-deubiquitinase interactions and influence in vivo signaling.

Authors:  Aaron H Phillips; Yingnan Zhang; Christian N Cunningham; Lijuan Zhou; William F Forrest; Peter S Liu; Micah Steffek; James Lee; Christine Tam; Elizabeth Helgason; Jeremy M Murray; Donald S Kirkpatrick; Wayne J Fairbrother; Jacob E Corn
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-25       Impact factor: 11.205

Review 2.  Proteolysis-Targeting Chimeras: Induced Protein Degradation as a Therapeutic Strategy.

Authors:  Philipp Ottis; Craig M Crews
Journal:  ACS Chem Biol       Date:  2017-03-20       Impact factor: 5.100

3.  An Mdm2 antagonist, Nutlin-3a, induces p53-dependent and proteasome-mediated poly(ADP-ribose) polymerase1 degradation in mouse fibroblasts.

Authors:  Shingo Matsushima; Naoyuki Okita; Misako Oku; Wataru Nagai; Masaki Kobayashi; Yoshikazu Higami
Journal:  Biochem Biophys Res Commun       Date:  2011-03-16       Impact factor: 3.575

Review 4.  Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin Lymphoma.

Authors:  John G Gribben; Nathan Fowler; Franck Morschhauser
Journal:  J Clin Oncol       Date:  2015-07-20       Impact factor: 44.544

5.  β-Trcp ubiquitin ligase and RSK2 kinase-mediated degradation of FOXN2 promotes tumorigenesis and radioresistance in lung cancer.

Authors:  Jia Ma; Yanwei Lu; Sheng Zhang; Yan Li; Jing Huang; Zhongyuan Yin; Jinghua Ren; Kai Huang; Li Liu; Kunyu Yang; Gang Wu; Shuangbing Xu
Journal:  Cell Death Differ       Date:  2018-02-02       Impact factor: 15.828

6.  De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling.

Authors:  Ingrid E Wertz; Karen M O'Rourke; Honglin Zhou; Michael Eby; L Aravind; Somasekar Seshagiri; Ping Wu; Christian Wiesmann; Rohan Baker; David L Boone; Averil Ma; Eugene V Koonin; Vishva M Dixit
Journal:  Nature       Date:  2004-07-18       Impact factor: 49.962

Review 7.  Cereblon and its downstream substrates as molecular targets of immunomodulatory drugs.

Authors:  Takumi Ito; Hiroshi Handa
Journal:  Int J Hematol       Date:  2016-07-26       Impact factor: 2.490

Review 8.  Effect of Stromal Cells in Tumor Microenvironment on Metastasis Initiation.

Authors:  Sen Guo; Chu-Xia Deng
Journal:  Int J Biol Sci       Date:  2018-11-13       Impact factor: 6.580

Review 9.  Recent Advances in the Discovery of Deubiquitinating Enzyme Inhibitors.

Authors:  Mark Kemp
Journal:  Prog Med Chem       Date:  2016-01-12

10.  Inhibition of UCHL1 by LDN-57444 attenuates Ang II-Induced atrial fibrillation in mice.

Authors:  Hai-Lian Bi; Yun-Long Zhang; Jie Yang; Qing Shu; Xiao-Lei Yang; Xiao Yan; Chen Chen; Zhi Li; Hui-Hua Li
Journal:  Hypertens Res       Date:  2019-11-07       Impact factor: 3.872

View more
  7 in total

1.  USP1 inhibition suppresses the progression of osteosarcoma via destabilizing TAZ.

Authors:  Putao Yuan; Zhenhua Feng; Hai Huang; Gangliang Wang; Zhijun Chen; Guang Xu; Ziang Xie; Zhiwei Jie; Xiangde Zhao; Qingliang Ma; Shiyu Wang; Yang Shen; Yizhen Huang; Ying Han; Huali Ye; Jiying Wang; Peihua Shi; Xuewu Sun
Journal:  Int J Biol Sci       Date:  2022-05-01       Impact factor: 10.750

2.  CRISPR screening of E3 ubiquitin ligases reveals Ring Finger Protein 185 as a novel tumor suppressor in glioblastoma repressed by promoter hypermethylation and miR-587.

Authors:  Kun Lin; Shang-Hang Shen; Feng Lu; Pengfeng Zheng; Shizhong Wu; Jingwei Liao; Xiaohang Jiang; Guangming Zeng
Journal:  J Transl Med       Date:  2022-02-19       Impact factor: 5.531

3.  Pan-Cancer Analysis Identifies CHD5 as a Potential Biomarker for Glioma.

Authors:  Lei Xu; Fengling Shao; Tengling Luo; Qijun Li; Dongmei Tan; Yi Tan
Journal:  Int J Mol Sci       Date:  2022-07-30       Impact factor: 6.208

4.  TRAF4 Promotes the Proliferation of Glioblastoma by Stabilizing SETDB1 to Activate the AKT Pathway.

Authors:  Hongyu Gu; Shunqin Zhu; Cheng Peng; Zekun Wei; Yang Shen; Chaoyu Yuan; He Yang; Hongjuan Cui; Liqun Yang
Journal:  Int J Mol Sci       Date:  2022-09-05       Impact factor: 6.208

5.  UbiComb: A Hybrid Deep Learning Model for Predicting Plant-Specific Protein Ubiquitylation Sites.

Authors:  Arslan Siraj; Dae Yeong Lim; Hilal Tayara; Kil To Chong
Journal:  Genes (Basel)       Date:  2021-05-11       Impact factor: 4.096

6.  Overexpression of ABCG2 Confers Resistance to MLN7243, a Ubiquitin-Activating Enzyme (UAE) Inhibitor.

Authors:  Zhuo-Xun Wu; Yuqi Yang; Jing-Quan Wang; Silpa Narayanan; Zi-Ning Lei; Qiu-Xu Teng; Leli Zeng; Zhe-Sheng Chen
Journal:  Front Cell Dev Biol       Date:  2021-07-14

Review 7.  Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges.

Authors:  Peng Ye; Xiaoxia Chi; Jong-Ho Cha; Shahang Luo; Guanghui Yang; Xiuwen Yan; Wen-Hao Yang
Journal:  Cells       Date:  2021-11-25       Impact factor: 6.600

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.